Scientific work

Doç. Dr. Sema Kaymaz Tahra

52 publications. The source of the information is stated next to each publication.

Back to profile

  1. Hematological Indices as Potential Biomarkers of Disease Activity in Ankylosing Spondylitis: LASSO-Based Multivariable Modelling

    Medicina, 2026

    DOI 10.3390/medicina62030497 PMID 41901578 1 citation (Europe PMC) Open-access full textSource: ORCID

  2. Acute Motor Axonal Neuropathy Coexisting With Ankylosing Spondylitis: A Case‐Based Review

    Case Reports in Immunology, 2026

    DOI 10.1155/crii/5406702 PMID 42221920 1 citation (Europe PMC) Open-access full textSource: ORCID

  3. Genetic susceptibility and validation of angiographic patterns in Takayasu arteritis

    Journal of Autoimmunity, 2025

    DOI 10.1016/j.jaut.2025.103496 PMID 41207179 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  4. ABS0104 Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.2016 Open-access full textSource: OpenAlex

  5. POS0953 VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU'S ARTERITIS

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.308 Open-access full textSource: OpenAlex

  6. VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU’S ARTERITIS

    Kocaeli Üniversitesi - AVESİS, 2025

    Source: OpenAlex

  7. Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms

    Kocaeli Üniversitesi - AVESİS, 2025

    Source: OpenAlex

  8. Turkish Rheumatology Society (Turkish Takayasu Arteritis Study Group) recommendations for the diagnosis, follow-up and the treatment of Takayasu's arteritis

    Clinical and Experimental Rheumatology, 2025

    DOI 10.55563/clinexprheumatol/lptjx1 PMID 40658482 1 citation (OpenAlex) Source: OpenAlex

  9. Involvement of Iliofemoral Arteries in PET/CT Is Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14238607 PMID 41375908 4 citations (OpenAlex) Open-access full textSource: OpenAlex

  10. ABS0067 BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.2015 Open-access full textSource: OpenAlex

  11. BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY.

    Kocaeli Üniversitesi - AVESİS, 2025

    Source: OpenAlex

  12. Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis

    Clinical and Experimental Rheumatology, 2025

    DOI 10.55563/clinexprheumatol/sghxo3 PMID 41930660 Open-access full textSource: OpenAlex

  13. BIOLOGICAL TREATMENT MAY BE AN OPTION AS FIRST STEROID-SPARING AGENT IN A SUBGROUP OF YOUNG TAKAYASU ARTERITIS PATIENTS WITH PROMINENT ACUTE PHASE REACTANTS AND CONSTITUTIONAL SYMPTOMS

    Trakya University's Institutional Open Access System (Trakya University), 2025

    DOI 10.1136/annrheumdis-2025-eular.a1618 Open-access full textSource: OpenAlex

  14. BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY

    Trakya University's Institutional Open Access System (Trakya University), 2025

    DOI 10.1136/annrheumdis-2025-eular.a1408 Source: OpenAlex

  15. Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu's Arteritis

    Trakya University's Institutional Open Access System (Trakya University), 2025

    Open-access full textSource: OpenAlex

  16. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis

    Seminars in Arthritis and Rheumatism, 2024

    DOI 10.1016/j.semarthrit.2024.152446 PMID 38669786 15 citations (OpenAlex) Source: OpenAlex

  17. Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study

    Clinical Rheumatology, 2024

    DOI 10.1007/s10067-024-06939-y PMID 38563865 8 citations (OpenAlex) Open-access full textSource: OpenAlex

  18. Romatolojide Güncel Tedaviler

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2736 Open-access full textSource: OpenAlex

  19. Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms

    Kocaeli Üniversitesi - AVESİS, 2024

    Source: OpenAlex

  20. Glucocorticoid toxicity index

    Acta Medica, 2024

    DOI 10.32552/2024.actamedica.1098 Open-access full textSource: ORCID

  21. Takayasu arteritine eşlik eden spondiloartrit spektrumundaki hastalıkların sıklığı ve hastalık seyrine etkisi.

    Kocaeli Üniversitesi - AVESİS, 2023

    Source: OpenAlex

  22. Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment

    Ulusal Romatoloji Dergisi, 2023

    DOI 10.4274/raed.galenos.2023.59144 Open-access full textSource: OpenAlex

  23. Development of the Takayasu Arteritis Integrated Disease Activity Index

    Arthritis Care & Research, 2023

    DOI 10.1002/acr.25275 PMID 38059340 17 citations (OpenAlex) Open-access full textSource: OpenAlex

  24. Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

    International journal of rheumatic diseases, 2022

    DOI 10.1111/1756-185x.14335 PMID 35603731 6 citations (Europe PMC) Open-access full textSource: Europe PMC

  25. Pregnancy in Takayasu's arteritis has a high risk of hypertension-related fetomaternal complications: A retrospective study of a Turkish cohort

    International journal of rheumatic diseases, 2022

    DOI 10.1111/1756-185x.14247 PMID 34791826 6 citations (Europe PMC) Source: Europe PMC

  26. Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

    Turkish Journal of Medical Sciences, 2022

    DOI 10.55730/1300-0144.5317 PMID 36161613 9 citations (Europe PMC) Open-access full textSource: ORCID

  27. Disease activity and prognosis in Takayasu’s arteritis,Takayasu arteritinde aktivite değerlendirmesi ve prognoz

    Journal of Turkish Society For Rheumatology, 2022

    DOI 10.4274/raed.galenos.2022.97752 Open-access full textSource: ORCID

  28. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab

    Seminars in Arthritis and Rheumatism, 2021

    DOI 10.1016/j.semarthrit.2021.09.010 PMID 34706312 43 citations (OpenAlex) Source: OpenAlex

  29. The prevalence of non-vascular pulmonary manifestations in Takayasu’s Arteritis patients: A Retrospective multi-centred Turkish cohort study

    Scandinavian Journal of Rheumatology, 2021

    DOI 10.1080/03009742.2021.1972535 PMID 34643164 4 citations (OpenAlex) Source: OpenAlex

  30. Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis.

    Kocaeli Üniversitesi - AVESİS, 2021

    Source: OpenAlex

  31. Childhood-onset versus adult-onset Takayasu arteritis: A study of 141 patients from Turkey

    Seminars in Arthritis and Rheumatism, 2021

    DOI 10.1016/j.semarthrit.2020.10.013 PMID 33383295 23 citations (Europe PMC) Source: ORCID

  32. HADS-depression score is a mediator for illness perception and daily life impairment in Takayasu’s arteritis

    Clinical Rheumatology, 2021

    DOI 10.1007/s10067-021-05719-2 PMID 33839991 9 citations (Europe PMC) Source: ORCID

  33. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study

    American Journal of Human Genetics, 2021

    DOI 10.1016/j.ajhg.2020.11.014 PMID 33308445 47 citations (Europe PMC) Open-access full textSource: ORCID

  34. The assessment of malnutrition and severity of gastrointestinal disease by using symptom-based questionnaires in systemic sclerosis: is it related to severe organ involvement or capillary rarefaction at microcirculation?

    Clin Exp Rheumatol, 2020

    PMID 32141434 7 citations (OpenAlex) Open-access full textSource: ORCID

  35. Assessment of damage in Takayasu‘s arteritis

    Seminars in Arthritis and Rheumatism, 2020

    DOI 10.1016/j.semarthrit.2020.04.003 PMID 32470706 19 citations (Europe PMC) Source: ORCID

  36. The assessment of malnutrition and severity of gastrointestinal disease using symptom-based questionnaires in systemic sclerosis: Is it related to severe organ involvement or capillary rarefaction at microcirculation?

    Clinical and Experimental Rheumatology, 2020

    Source: ORCID

  37. AB0575 THE EFFECT OF METABOLIC SYNDROME ON CARDIOVASCULAR DISEASE AND CUMULATIVE ORGAN DAMAGE IN TAKAYASU'S ARTERITIS

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.4055 Open-access full textSource: OpenAlex

  38. Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group.

    Kocaeli Üniversitesi - AVESİS, 2019

    Source: OpenAlex

  39. CAN A ONE-HOUR QUANTITATIVE ASSESSMENT OF FDG-PET-CT (MODIFIED-PETVAS) BE USEFUL IN TAKAYASU'S ARTERITIS?

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6843 Open-access full textSource: ORCID

  40. 257. CAN A ONE-HOUR QUANTITATIVE ASSESSMENT OF FDG-PET-CT (MODIFIED-PETVAS) BE USEFUL IN TAKAYASU’S ARTERITIS?

    Rheumatology, 2019

    DOI 10.1093/rheumatology/kez062.031 Source: OpenAlex

  41. AB0223 ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS: THE COMPARISON BETWEEN REVISED EUSTAR AND ESCSG ACTIVITY INDEXES

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6167 Open-access full textSource: OpenAlex

  42. 256. ASSESSMENT OF DAMAGE IN TAKAYASU ARTERITIS PATIENTS WITH VASCULITIS DAMAGE INDEX (VDI) AND TAKAYASU ARTERITIS DAMAGE SCORE (TADS)

    Rheumatology, 2019

    DOI 10.1093/rheumatology/kez062.030 Open-access full textSource: OpenAlex

  43. AB0596 ASSESMENT OF DAMAGE IN TAKAYASU ARTERITIS PATIENTS WITH VASCULITIS DAMAGE INDEX (VDI) AND TAKAYASU ARTERITIS DAMAGE SCORE (TADS)

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6025 Open-access full textSource: OpenAlex

  44. FRI0299 THE PREVALENCE OF NON-VASCULAR PULMONARY MANIFESTATIONS IN PATIENTS WITH TAKAYASU' ARTERITIS: A RETROSPECTIVE MULTI-CENTERED COHORT STUDY

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.3685 Open-access full textSource: OpenAlex

  45. Takayasu arteritli hastalarda non-vasküler akciğer tutulum sıklığı: Çok merkezli retrospektif kohort sonuçları

    Kocaeli Üniversitesi - AVESİS, 2019

    Source: OpenAlex

  46. Methodology of a new inflammatory arthritis registry: TReasure

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018

    DOI 10.3906/sag-1807-200 PMID 30119164 16 citations (OpenAlex) Open-access full textSource: OpenAlex

  47. Geç başlangıçlı spondilartrit hastalarında TNF inhibitörü tedavilerinin sürekliliği ve etkinliği: TReasure gerçek yaşam verileri

    Bursa Uludag University - AVESIS, 2018

    Source: OpenAlex

  48. Takayasu arteritinde hastalık ile ilişkili gebelik prognozu.

    Kocaeli Üniversitesi - AVESİS, 2018

    Source: OpenAlex

  49. Geç bafllang›çl› spondilartrit hastalar›nda TNF inhibitörütedavilerinin süreklili¤i ve etkinli¤i: TReasure gerçekyaflam verileri

    AYBU AVESIS, 2018

    Source: OpenAlex

  50. Certolizumab pegol in the treatment of takayasu arteritis

    Rheumatology (United Kingdom), 2018

    DOI 10.1093/rheumatology/key197 PMID 30010945 18 citations (Europe PMC) Open-access full textSource: ORCID